Abaloparatide Real-World Patient Experience Study.

Gold DT, Weiss R, Beckett T, Deal C, Epstein RS, James AL, Kernaghan JM, Mohseni M, Spiegel M, Vokes T, Roberts J, Bailey T, Wang Y, Williams SA

JBMR plus4 Feb 2021Cited by 7 (Europe PMC)

PMID33778325PMCIDPMC7990148DOI10.1002/jbm4.10457PepBankPUB-33778325

Download PDF PubMedAsk about this study

Jump to 15 results

Summary

Despite the availability of various osteoporosis treatments, adherence remains suboptimal. One contributing factor may be patient experience with therapy. This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection. Eight geographically diverse secondary care sites in the United States participated (n = 193). Mean ± SD age was 67.4 ±8.62 years. Most patients (86%) were satisfied with the ABL regimen, especially with ease of preparation (82%), ease of storage (87%), and storage convenience (89%), an attribute 83% of the patients thought was important. The majority of patients reported complete satisfaction with the ABL regimen allowing for their ability to conduct daily activities (85%) and convenience to fit into their daily schedule (84%). All reported taking ABL as directed, by injection in the lower abdomen, and 83% of patients reported medium or high adherence. Patients were satisfied with the needle size (76% completely satisfied), and 93% reported never deliberately missing a dose. Although injecting medication (18%) and higher out-of-pocket costs (17%) were deemed the most bothersome attributes, the majority (69%) noted their healthcare team understands how osteoporosis impacts their lives. In multivariable analyses, ease of preparation (OR = 2.62; 95% CI, 1.01-6.81; p = 0.048) and fracture history (OR = 1.72; 95% CI, 1.03-2.86; p = 0.037) were significantly associated with overall satisfaction. Ease of preparation was a predictor of higher satisfaction with treatment convenience (coefficient = 13.60; 95% CI, 8.08-19.12; p = 0.00). Remembering to take the medication was a significant predictor of self-reported adherence (OR = 16.66; 95% CI, 3.30-84.24; p = 0.001). In conclusion, the majority of patients were satisfied with ABL and found it convenient/easy to prepare and store. High self-reported adherence may be associated with positive patient experience including ease of use and adequate support from healthcare providers. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study15

12 results from studies that gave the peptide. 12 results from people.

01HumanObservational studyOther
Among postmenopausal women at high fracture risk, 86% reported satisfaction with abaloparatide.
In plain wordsAmong women at high fracture risk, 86% reported satisfaction with abaloparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableOverall regimen satisfaction
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · injection in lower abdomenAs given in this study (human).
Measurements
Satisfied patients
86%
overall regimen
Source sentences
Summary
Most patients (86%) were satisfied with the ABL regimen, especially with ease of preparation (82%), ease of storage (87%), and storage convenience (89%), an attribute 83% of the patients thought was important.
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
Show in the study text Report a problemFND-3377832501
02HumanObservational studyOther
Among women using abaloparatide, 82% reported satisfaction with ease of preparation.
In plain wordsAmong women using abaloparatide, 82% reported satisfaction with ease of preparation.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicablePreparation satisfaction
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · injection in lower abdomenAs given in this study (human).
Measurements
Satisfied patients
82%
ease of preparation
Source sentences
Summary
Most patients (86%) were satisfied with the ABL regimen, especially with ease of preparation (82%), ease of storage (87%), and storage convenience (89%), an attribute 83% of the patients thought was important.
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
Show in the study text Report a problemFND-3377832502
03HumanObservational studyOther
Among women using abaloparatide, 87% reported satisfaction with ease of storage.
In plain wordsAmong women using abaloparatide, 87% reported satisfaction with ease of storage.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableStorage satisfaction
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · injection in lower abdomenAs given in this study (human).
Measurements
Satisfied patients
87%
ease of storage
Source sentences
Summary
Most patients (86%) were satisfied with the ABL regimen, especially with ease of preparation (82%), ease of storage (87%), and storage convenience (89%), an attribute 83% of the patients thought was important.
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
Show in the study text Report a problemFND-3377832503
04HumanObservational studyOther
Among women using abaloparatide, 89% reported satisfaction with storage convenience.
In plain wordsAmong women using abaloparatide, 89% reported satisfaction with storage convenience.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableStorage convenience satisfaction
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · injection in lower abdomenAs given in this study (human).
Measurements
Satisfied patients
89%
storage convenience
Source sentences
Summary
Most patients (86%) were satisfied with the ABL regimen, especially with ease of preparation (82%), ease of storage (87%), and storage convenience (89%), an attribute 83% of the patients thought was important.
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
Show in the study text Report a problemFND-3377832504
05HumanObservational studyOther
Among women using abaloparatide, 85% were completely satisfied with its compatibility with daily activities.
In plain wordsAmong women using abaloparatide, 85% were completely satisfied with its compatibility with daily activities.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableSatisfaction with daily activities
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · injection in lower abdomenAs given in this study (human).
Measurements
Completely satisfied
85%
daily activities
Source sentences
Summary
The majority of patients reported complete satisfaction with the ABL regimen allowing for their ability to conduct daily activities (85%) and convenience to fit into their daily schedule (84%).
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
Show in the study text Report a problemFND-3377832506
06HumanObservational studyOther
Among women using abaloparatide, 84% were completely satisfied with its fit into their daily schedule.
In plain wordsAmong women using abaloparatide, 84% were completely satisfied with its fit into their daily schedule.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableSatisfaction with daily schedule convenience
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · injection in lower abdomenAs given in this study (human).
Measurements
Completely satisfied
84%
daily schedule
Source sentences
Summary
The majority of patients reported complete satisfaction with the ABL regimen allowing for their ability to conduct daily activities (85%) and convenience to fit into their daily schedule (84%).
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
Show in the study text Report a problemFND-3377832507
07HumanObservational studyOther
All surveyed women reported taking abaloparatide as directed by lower-abdominal injection.
In plain wordsAll surveyed women reported taking abaloparatide as directed by lower-abdominal injection.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableReported administration as directed
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · injection in lower abdomenAs given in this study (human).
Source sentences
Summary
All reported taking ABL as directed, by injection in the lower abdomen, and 83% of patients reported medium or high adherence.
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
Show in the study text Report a problemFND-3377832508
08HumanObservational studyOther
Among women using abaloparatide, 83% reported medium or high adherence.
In plain wordsAmong women using abaloparatide, 83% reported medium or high adherence.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableMedium or high adherence
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · injection in lower abdomenAs given in this study (human).
Measurements
Medium or high adherence
83%
self-report
Source sentences
Summary
All reported taking ABL as directed, by injection in the lower abdomen, and 83% of patients reported medium or high adherence.
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
Show in the study text Report a problemFND-3377832509
09HumanObservational studyOther
Among women using abaloparatide, 76% reported complete satisfaction with needle size.
In plain wordsAmong women using abaloparatide, 76% reported complete satisfaction with needle size.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableNeedle size satisfaction
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · injection in lower abdomenAs given in this study (human).
Measurements
Completely satisfied
76%
needle size
Source sentences
Summary
Patients were satisfied with the needle size (76% completely satisfied), and 93% reported never deliberately missing a dose.
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
Show in the study text Report a problemFND-3377832510
10HumanObservational studyOther
Among women using abaloparatide, 93% reported never deliberately missing a dose.
In plain wordsAmong women using abaloparatide, 93% reported never deliberately missing a dose.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableNever deliberately missing a dose
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · injection in lower abdomenAs given in this study (human).
Measurements
Never deliberately missing a dose
93%
self-report
Source sentences
Summary
Patients were satisfied with the needle size (76% completely satisfied), and 93% reported never deliberately missing a dose.
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
Show in the study text Report a problemFND-3377832511
11HumanObservational studyOther
Among women using abaloparatide, 18% identified injecting medication as a most bothersome attribute.
In plain wordsAmong women using abaloparatide, 18% identified injections as a most bothersome attribute.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableInjection burden
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · injection in lower abdomenAs given in this study (human).
Measurements
Patients identifying burden
18%
injecting medication
Source sentences
Summary
Although injecting medication (18%) and higher out-of-pocket costs (17%) were deemed the most bothersome attributes, the majority (69%) noted their healthcare team understands how osteoporosis impacts their lives.
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
Show in the study text Report a problemFND-3377832512
12HumanObservational studyOther
Among women using abaloparatide, 17% identified higher out-of-pocket costs as a most bothersome attribute.
In plain wordsAmong women using abaloparatide, 17% identified higher personal costs as a most bothersome attribute.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableOut-of-pocket cost burden
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · injection in lower abdomenAs given in this study (human).
Measurements
Patients identifying burden
17%
out-of-pocket costs
Source sentences
Summary
Although injecting medication (18%) and higher out-of-pocket costs (17%) were deemed the most bothersome attributes, the majority (69%) noted their healthcare team understands how osteoporosis impacts their lives.
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
Show in the study text Report a problemFND-3377832513

Studies that did not test the peptide alone3

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

13HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among women using abaloparatide, 83% considered storage convenience important.
In plain wordsAmong women using abaloparatide, 83% considered storage convenience important.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableImportance of storage convenience
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Measurements
Patients considering attribute important
83%
storage convenience
Source sentences
Summary
Most patients (86%) were satisfied with the ABL regimen, especially with ease of preparation (82%), ease of storage (87%), and storage convenience (89%), an attribute 83% of the patients thought was important.
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3377832505
14HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among women using abaloparatide, ease of preparation was linked to higher overall satisfaction, with an odds ratio of 2.62.
In plain wordsAmong women using abaloparatide, easier preparation was linked to higher overall satisfaction.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreasePreparation ease association with overall satisfaction
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Measurements
Odds ratio
2.62 OR
overall satisfaction
95% CI
1.01 to 6.81 OR
overall satisfaction
Source sentences
Summary
In multivariable analyses, ease of preparation (OR = 2.62; 95% CI, 1.01-6.81; p = 0.048) and fracture history (OR = 1.72; 95% CI, 1.03-2.86; p = 0.037) were significantly associated with overall satisfaction.
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3377832515
15HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among women using abaloparatide, preparation ease predicted higher convenience satisfaction, with a coefficient of 13.60.
In plain wordsAmong women using abaloparatide, easier preparation was linked to greater satisfaction with treatment convenience.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreasePreparation ease association with convenience satisfaction
Study
n = 193
Outcome group
Patient-reported outcomes · Whole body
Measurements
Coefficient
13.6 score units
convenience satisfaction
95% CI
8.08 to 19.12 score units
convenience satisfaction
Source sentences
Summary
Ease of preparation was a predictor of higher satisfaction with treatment convenience (coefficient = 13.60; 95% CI, 8.08-19.12; p = 0.00).
2 context sentences(design, population, supporting numbers)
Summary · context
This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection.
Summary · context
Eight geographically diverse secondary care sites in the United States participated (n = 193).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3377832517

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.